Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition

Freeman, Marlene P.; Hirschberg, April; Wang, Betty; Petrillo, Laura; Connors, Stephanie; Regan, Susan; Joffe, Hadine; Cohen, Lee S.

doi:10.1016/j.maturitas.2013.03.007

Cited by 20 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DXT.HCl, N-methyl-3-(napthalen-1-yloxy)-3-(thiophene-2-yl) propan-1-amine hydrochloride (Scheme 1) is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) originally developed as an antidepressant and is currently recommended for maintenance treatment of major depressive disorder [1]. The drug is approved by the US Food and Drug administration for the treatment of diabetic polyneuropathy and is recommended as a first line treatment for this purpose [2].…”

Section: Introductionmentioning

confidence: 99%

Trace Determination of Duloxetine HCl in Formulation and Spiked Human Serum at a Carbon Paste Electrode

Hassanein¹,

Moharram²,

Oraiby³

et al. 2017

AJAC

View full text Add to dashboard Cite

The electrochemical behavior of duloxetine HCl (DXT.HCl) at a carbon paste electrode (CPE) was achieved by cyclic voltammetry and a mechanism of its oxidation was reported and illustrated. A sensitive linear sweep and square-wave adsorptive anodic stripping voltammetry methods were described for trace determination of DXT.HCl. Introduction: DXT.HCl, N-methyl-3-(nap-thalen-1-yloxy)-3-(thiophene-2-yl) propan-1-amine hydrochloride is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) originally developed as an antidepressant and is currently recommended for maintenance treatment of major depressive disorder. Methods: Electrochemical behavior was studied using cyclic voltammetric method, and the analytical application was studied using linear sweep and square wave voltammetric methods. Solution pH has been measured by pH meter. Results: The process on the surface of carbon paste electrode was found to be irreversible and diffusion-controlled. The number of proton and electron transferred were calculated. Possible reaction mechanism taking place on the surface of electrode was proposed. Calibration plot constructed using square wave voltammetric technique was used for quantitative analysis in pharmaceutical and human serum samples. Limit of detection (LOD) and limit of quantification (LOQ) were calculated. Conclusions: In the present work, we described the electrochemical behavior of DXT.HCl drug. Two precise linear sweep and square wave adsorptive anodic stripping voltammetry methods have been described for its trace quantitation in pharmaceutical formulation and human serum. The method shows the development of a sensor for selective and sensitive determination of DXT.HCl.How to cite this paper: Hassanein, A.M.,

show abstract

Section: Introductionmentioning

confidence: 99%

Trace Determination of Duloxetine HCl in Formulation and Spiked Human Serum at a Carbon Paste Electrode

Hassanein¹,

Moharram²,

Oraiby³

et al. 2017

AJAC

View full text Add to dashboard Cite

show abstract

“…1), is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) recommended for the maintenance treatment of major depressive disorder. Originally developed as an antidepressant (Freeman et al 2013), this drug has now gained approval by the US FDA for several other therapeutic indications including the treatment of neuropathic pain especially diabetic polyneuropathy (first-line treatment) (Goldstein et al 2005), management of fibromyalgia (Bennett et al 2012), generalized anxiety disorder (Ball et al 2013), stress urinary incontinence (SUI) (Mihaylova et al 2010;Leewen et al 2008) and most recently, for the treatment of chronic musculoskeletal pain. It has an average half-life of 12 h with 40-50% bioavailability.…”

Section: Introductionmentioning

confidence: 99%

Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride

Singh

Bali

2016

J Anal Sci Technol

View full text Add to dashboard Cite

Background: Duloxetine hydrochloride is an antidepressant drug also approved for diabetic neuropathy, anxiety disorders, and fibromyalgia requiring repeated administration on chronic basis. The objective of this study was to develop a transdermal drug delivery system for duloxetine hydrochloride as a once daily dosage form. Methods: Transdermal patches were prepared by solvent evaporation method employing controlled release grades of HPMC in presence or absence of plasticizer PEG-400. FTIR and Differential scanning calorimetry ruled out drug polymer interactions. Standard procedures were used to analyze the prepared films for various physicochemical parameters, drug release (Franz diffusion cell) and skin irritation test. Results: The formulations were uniform in their physical characteristics with low water vapor absorption, moisture loss and water vapor transmission implying excellent quality and uniformity in patch characteristics. The patches were devoid of hypersensitivity reactions on rat skin. The in-vitro and ex-vivo drug release studies for all the formulations showed that the first dose of the drug was released in 2.0-3.0 h and nearly complete release (94%) was achieved in 24 h. Conclusions: Transdermal patches were successfully prepared for duloxetine hydrochloride and their evaluation suggested excellent quality and uniformity in patch characteristics. This can have potential applications in therapeutic arena offering advantages in terms of reduced dosing frequency, improved patient compliance and bioavailability.

show abstract

“…The decrease of serum E2 level in vivo will negatively feedback elevate FSH, and further lead to significantly decreased expression of 5-HT and DA. Since abnormal secretion of estrogen is the most important factor for perimenopause and stress is a significant trigger for depression, the mouse model of perimenopausal depression based on continuous stress on ovariectomized female mice was set up (Freeman et al, 2013). Subsequently, the activity of the mice was studied, and changes to monoamine neurotransmitter levels in brain and hormone levels in the serum.…”

Section: Discussionmentioning

confidence: 99%

Effect of Cynomorium flavonoids on mouse model of perimenopausal depression

Miao

Wang

et al. 2016

Bangladesh J Pharmacol

View full text Add to dashboard Cite

The effect of Cynomorium flavonoids on mice model of perimenopausal depression was studied. Ovariectomized female mice (n=70) were randomly divided into 7 groups evenly and treated with different concentrations (5-400 mg/mL, of cynomorium flavonoids, gengnian'an capsule and soy isoflavones soft capsule. The model related groups were applied with different stress for consecutive 18 days. Behavior tests were performed on the 27th, 28th, and 29th days of administration. The concentrations of estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in serum as well as the 5-hydroxytryptamine (5-HT) and dopamine (DA) in brain homogenates were determined after the last administration. It was found that cynomorium flavonoids have significant effects on the mice with perimenopausal depression.

show abstract

Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition

Cited by 20 publications

References 28 publications

Trace Determination of Duloxetine HCl in Formulation and Spiked Human Serum at a Carbon Paste Electrode

Trace Determination of Duloxetine HCl in Formulation and Spiked Human Serum at a Carbon Paste Electrode

Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride

Effect of Cynomorium flavonoids on mouse model of perimenopausal depression

Contact Info

Product

Resources

About